BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Takakura K, Oikawa T, Tomita Y, Mizuno Y, Nakano M, Saeki C, Torisu Y, Saruta M. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma. World J Gastroenterol 2018; 24(18): 1989-1994 [PMID: 29760542 DOI: 10.3748/wjg.v24.i18.1989]
URL: https://www.wjgnet.com/1007-9327/full/v24/i18/1989.htm
Number Citing Articles
Yvonne Oligschlaeger, Ronit Shiri-Sverdlov. NAFLD Preclinical Models: More than a Handful, Less of a Concern?Biomedicines 2020; 8(2): 28 doi: 10.3390/biomedicines8020028
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, Tracy Robson, Stephanie Annett. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targetsFrontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1148934
Utibe-Abasi S. Udoh, Moumita Banerjee, Pradeep K. Rajan, Juan D. Sanabria, Gary Smith, Mathew Schade, Jacqueline A. Sanabria, Yuto Nakafuku, Komal Sodhi, Sandrine V. Pierre, Joseph I. Shapiro, Juan R. Sanabria. Tumor-Suppressor Role of the α1-Na/K-ATPase Signalosome in NASH Related Hepatocellular CarcinomaInternational Journal of Molecular Sciences 2022; 23(13): 7359 doi: 10.3390/ijms23137359
Edwige Schreyer, Cathy Obringer, Nadia Messaddeq, Bruno Kieffer, Paul Zimmet, Alexander Fleming, Tarekegn Geberhiwot, Vincent Marion. PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In VivoDiabetes 2022; 71(9): 2034 doi: 10.2337/db22-0058
Mark A. Febbraio, Saskia Reibe, Shabnam Shalapour, Geraldine J. Ooi, Matthew J. Watt, Michael Karin. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?Cell Metabolism 2019; 29(1): 18 doi: 10.1016/j.cmet.2018.10.012
Daniel Neureiter, Sebastian Stintzing, Tobias Kiesslich, Matthias Ocker. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targetsWorld Journal of Gastroenterology 2019; 25(25): 3136-3150 doi: 10.3748/wjg.v25.i25.3136
R. Rama Suresh, Shanu Jain, Zhoumou Chen, Dilip K. Tosh, Yanling Ma, Maren C. Podszun, Yaron Rotman, Daniela Salvemini, Kenneth A. Jacobson. Design and in vivo activity of A3 adenosine receptor agonist prodrugsPurinergic Signalling 2020; 16(3): 367 doi: 10.1007/s11302-020-09715-0
Yewei Liu, Shuncong Wang, Xiaohui Zhao, Yuanbo Feng, Guy Bormans, Johan Swinnen, Raymond Oyen, Gang Huang, Yicheng Ni, Yue Li. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology CorrelationDiagnostics 2020; 10(2): 78 doi: 10.3390/diagnostics10020078
Daniel Jahn, Stefan Kircher, Heike M. Hermanns, Andreas Geier. Animal models of NAFLD from a hepatologist's point of viewBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019; 1865(5): 943 doi: 10.1016/j.bbadis.2018.06.023
Noriko Suzuki-Kemuriyama, Akari Abe, Sae Nakane, Megumi Yuki, Katsuhiro Miyajima, Dai Nakae, Fei Luo. Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changesPLOS ONE 2023; 18(8): e0287657 doi: 10.1371/journal.pone.0287657
Scott A. Reisman, Deborah A. Ferguson, Chun‐Yue I. Lee, Joel W. Proksch. Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitisJournal of Biochemical and Molecular Toxicology 2020; 34(9) doi: 10.1002/jbt.22526